ACIP website.The clinical trial for the Moderna COVID-19 vaccine demonstrated very high efficacy of the 2-dose regimen against symptomatic, laboratory-confirmed COVID-19.1,2 The overall efficacy* was 94.1% (95% Confidence Interval [CI]: 89.3%, 96.8%).
Consistent high efficacy (≥86%) was observed across age, sex, race, ethnicity, and among those at risk for severe COVID-19.Nine persons in the placebo group and one in the vaccine group were hospitalized with COVID-19.3 Vaccine efficacy against hospitalization due to COVID-19 was 89% (95% CI: 13%, 89%).
Deaths were also uncommon, 6 in the vaccine group and 7 in the placebo group.Post-marketing surveillance will be critical to detect any rare serious adverse events which were not identified in.